Category Archives: Novartis Case

At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

Posted on May 27, 2019 by donttradeourlivesaway

Source: Statnews 27th May, 2019   The Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world. … Continue reading →

Posted in Gene Therapy, Novartis Case | Leave a comment

Five years after the Indian Supreme Court’s novartis verdict

Posted on May 31, 2018 by donttradeourlivesaway

Source: Intellectual Property Watch | May 21, 2018 On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about … Continue reading →

Posted in Novartis Case, Sec 3 (d) | Leave a comment

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Posted on March 2, 2018 by donttradeourlivesaway

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading →

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

Can drug firms increase health-care access, or just their profits?

Posted on December 13, 2016 by donttradeourlivesaway

Anne Aerts, head of Novartis Foundation, addresses a conference in Basel, Switzerland, looking at the role of drug companies in building health systems. (Credit: Kiara Barnes/Novartis) BASEL, Switzerland — The controversial Swiss pharmaceutical company Novartis has started work to expand … Continue reading →

Posted in Drug prices, Novartis Case, Uncategorized | 2 Comments

As US Trade Representative Arrives in Delhi, MSF Urges India to Stand Strong Against Attack on Affordable Medicines

Posted on November 26, 2014 by donttradeourlivesaway

Source: MSF Access Campaign New Delhi, 25 November 2014—As US Trade Representative Michael Froman meets high-ranking Indian officials to likely pressure the government to weaken its pro-public health patent law, Doctors Without Borders/ Médecins Sans Frontières (MSF) urged the new … Continue reading →

Posted in Compulsory Licensing, Innovation, IP Rights, Novartis Case, Out of Cycle Review (OCR), Patent Injunction, Patents, Right to Health, Sec 3 (d), Trade Policy Forum, TRIPS plus, US pressure on India, USTR 301 report | Leave a comment

South Centre concerned over US pressure on India’s IP regime

Posted on November 12, 2014 by donttradeourlivesaway

Source: TWN Geneva, 11 Nov (Kanaga Raja) — The South Centre has expressed concern over the pressures being placed on India by the United States Trade Representative (USTR) through the out-of-cycle review of the country’s intellectual property (IP) laws and … Continue reading →

Posted in Compulsory Licensing, IP Rights, IPR policy, Novartis Case, Out of Cycle Review (OCR), Patents, Sec 3 (d), Special 301 report, TRIPS flexibilities, US pressure on India | Leave a comment

Cipla-Novartis patent row: DIPP looking into merit of case

Posted on November 5, 2014 by donttradeourlivesaway

Source: Business Standard The Commerce and Industry Ministry is looking into the merit of Cipla’s demand for revocation of patents of Swiss drug major Novartis for respiratory drug Indacaterol citing the need for public health access. The Department of Industrial … Continue reading →

Posted in Generics, Indian Patent Law, IP Rights, Novartis Case | Tagged , , | Leave a comment

Is India pulling the leg?

Posted on October 21, 2014 by donttradeourlivesaway

Source: The Asian Age The Modi government has abandoned the fig leaf of adherence to public health goals… The first salvo was fired by Nirmala Sitharaman, signalling prior to Mr Modi’s visit to the US that India was willing to … Continue reading →

Posted in Compulsory Licensing, Generics, Hepatitis C, IP Rights, IPR policy, Novartis Case, Out of Cycle Review (OCR), Patents, Right to Health, Sec 3 (d), Sofosbuvir, TRIPS, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

Inside Views: USTR’s Investigations On IP Rights Against India: Is There A Tenable Case?

Posted on October 21, 2014 by donttradeourlivesaway

Source: Ip-Watch On 14th October, the US Trade Representative (USTR) began the out-of-cycle review (OCR) of India’s intellectual property (IP) laws, the mandate which it gave itself in the 2014 Special 301 Report. Like several years in the past, the … Continue reading →

Posted in Compulsory Licensing, Innovation, Novartis Case, Out of Cycle Review (OCR), Patents, TRIPS, US India BIT, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

Why did Modi agree to give away India’s patent sovereignty to Americans?

Posted on October 8, 2014 by donttradeourlivesaway

Source: First Post With the hype of his Madison Square Garden show overshadowing everything else, Prime Minister Narendra Modi’s US visit was dubbed as a great bilateral victory for India. As the popular consensus went, Modi wowed both the Indian … Continue reading →

Posted in Innovation, IP Rights, IPR policy, Novartis Case, Patents, Right to Health, TRIPS flexibilities, US pressure on India | 1 Comment